Aging Options

Experimental drug study slows cognitive decline in some Alzheimer's cases

Save as PDF

Eli Lilly and Company announced Oct. 8 that a second look at an experimental drug therapy called solanezumab that targets mild to moderate Alzheimer’s disease, found the cognitive decline in study participants slowed by 34 percent.  A full report and study results can be found here.  http://www.seniorjournal.com/NEWS/Alzheimers/2012/20121009-Alzheimers_Patients.htm

Need assistance planning for your successful retirement? Give us a call! 1.877.762.4464

Learn how 70% of retirement plans fail and what you can do to avoid this.

Find out more about LifePlanning

0
Your Cart is empty!

It looks like you haven't added any items to your cart yet.

Browse Products
Powered by Caddy
Skip to content